MCW researcher to study gene therapies for hemophilia

May 26, 2015

A researcher at the Medical College of Wisconsin (MCW) has received a four-year, $1.5 million dollar grant from the National Institutes of Health's National Heart, Lung, and Blood Institute to continue her study of blood platelet gene therapies for hemophilia A, a genetic bleeding disorder.

Qizhen Shi, MD, PhD, associate professor of pediatric hematology at MCW and an investigator at the Blood Research Institute at BloodCenter of Wisconsin, focuses her work on finding therapies for hemophilia A patients, including those with inactivating antibodies. Immune response often precludes any effective therapies to treat the disease.

Dr. Shi's team previously discovered a "clinically translatable gene therapy protocol" - essentially a gene delivery system that introduces the production of therapeutic clotting proteins in platelets by which the inhibition of inactivating antibodies is circumvented.

"The development of inhibitory antibodies against (blood-clotting factors) is not only a severe and important complication of protein replacement therapy, but also a major concern in gene therapy of hemophilia A." Shi said. "Generation of such inhibitors might potentially preclude gene therapy for hemophilia A. In this project, we propose to investigate a novel gene therapy approach that will provide therapeutic FVIII protein and induce immune tolerance for hemophilia A."
This project is funded by NIH grant 2R01 HL102035-06.

Medical College of Wisconsin

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to